Sensitivity to sulfonamides, severe renal or hepatic impairment, porphyria, SLE; infants <2 mth; pregnancy (3rd trimester), lactation.
|
Renal insufficiency, elderly, blood dyscrasias, G6PD deficiency, AIDS.
|
Nausea, vomitting, diarrhoea, hypersensitivity skin reaction, hypothyroidism, crystalluria, renal impairment , blood dyscrasias, kernicterus in premature neonates. Potentially Fatal: Stevens-Johnson syndrome, agranulocytosis and aplastic anaemia.
|
Concurrent use may increase phenytoin and methotrexate levels; increased risk of bleeding with warfarin and acenocoumarol; may potentiates antidiabetic effect of sulfonylureas. Potentially Fatal: Increased risk of blood dyscrasias with clozapine and pyrimethamine.
|
Interference with tests for urea, creatinine, urinary glucose, urobilinogen.
|
Description: Mechanism of Action: Sulfamoxole interferes with nucleic acid synthesis in microorganisms by blocking the conversion of p-aminobenzoic acid to the coenzyme dihydrofolic acid.
|
|
|
Disclaimer: This information is independently developed by MIMS based on Sulfamoxole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2026 MIMS. All rights reserved. Powered by MIMS.com